LENZ Therapeutics, Inc.
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade LENZ Therapeutics, Inc. 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LENZ
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia.
CEOEvert B. Schimmelpennink
CEOEvert B. Schimmelpennink
Employees42
Employees42
HeadquartersSolana Beach, California
HeadquartersSolana Beach, California
Founded2013
Founded2013
Employees42
Employees42
LENZ Key Statistics
Market cap544.57M
Market cap544.57M
Price-Earnings ratio-8.13
Price-Earnings ratio-8.13
Dividend yield—
Dividend yield—
Average volume1.66M
Average volume1.66M
High today$17.67
High today$17.67
Low today$16.60
Low today$16.60
Open price$16.72
Open price$16.72
Volume315.76K
Volume315.76K
52 Week high$50.40
52 Week high$50.40
52 Week low$15.70
52 Week low$15.70
Stock Snapshot
LENZ Therapeutics, Inc.(LENZ) stock is priced at $17.33, giving the company a market capitalization of 544.57M. It carries a P/E multiple of -8.13.
On 2025-12-25, LENZ Therapeutics, Inc.(LENZ) stock traded between a low of $16.60 and a high of $17.67. Shares are currently priced at $17.33, which is +4.4% above the low and -1.9% below the high.
The LENZ Therapeutics, Inc.(LENZ)'s current trading volume is 315.76K, compared to an average daily volume of 1.66M.
In the last year, LENZ Therapeutics, Inc.(LENZ) shares hit a 52-week high of $50.40 and a 52-week low of $15.70.
In the last year, LENZ Therapeutics, Inc.(LENZ) shares hit a 52-week high of $50.40 and a 52-week low of $15.70.
Analyst ratings
100%
of 7 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own LENZ. This list is generated using Robinhood data, and it’s not a recommendation.